Diffuse Midline Glioma, H3 K27M-Mutant — Trials

Diffuse Midline Glioma, H3 K27M-Mutant — Trials · CancerIndex

Clinical trials

Registered studies

28 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 17
Recruiting: 13
Ph III recruiting: 1
Growth YoY: —
Industry share: 29%
Top sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (5)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02960230	H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas	completed	Phase 1 / Phase 2	50	Sabine Mueller, MD, PhDOTHER	2	Jan 22, 2025	clinicaltrials
NCT01922076	Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	completed	Phase 1	46	National Cancer Institute (NCI)NIH	2	Jan 31, 2024	clinicaltrials